^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LPX EWS/FL1 T1
i
Other names: pbi-shRNA EWS/FLI1 type 1 LPX, pbi-shRNA EWS/FLI1 type 1 lipoplex, pbi-functional short hairpin RNA EWS/FLI1 type 1 lipoplex, LPX EWS/FL1 T1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Gradalis
Drug class:
Gene transference
Related drugs:
1year
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma (clinicaltrials.gov)
P1, N=7, Completed, Gradalis, Inc. | N=28 --> 7
Enrollment change • Metastases
|
LPX EWS/FL1 T1
over1year
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma (clinicaltrials.gov)
P1, N=28, Completed, Gradalis, Inc. | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2023 | Trial primary completion date: Jun 2023 --> Mar 2023
Trial completion • Trial completion date • Trial primary completion date • Metastases
|
EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
|
LPX EWS/FL1 T1
over1year
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma (clinicaltrials.gov)
P1, N=28, Active, not recruiting, Gradalis, Inc. | Trial primary completion date: Jan 2023 --> Jun 2023
Trial primary completion date • Metastases
|
EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
|
LPX EWS/FL1 T1
over2years
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma (clinicaltrials.gov)
P1, N=28, Active, not recruiting, Gradalis, Inc. | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Jan 2022 --> Jan 2023
Trial completion date • Trial primary completion date
|
EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor)
|
LPX EWS/FL1 T1
Share via
